ATRX gene variants may play an important role in identifying more effectively those patients who will have an increased risk of developing chronic or indolent MYCN non-amplified neuroblastoma, and should be considered for future target therapies and therapeutic approaches. This evidence concerns the gene ATRX and neuroblastoma.